Padmanabh P. Bhatt Sells 700 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $38.69 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.88. The business has a 50-day moving average price of $37.10 and a 200 day moving average price of $34.39. The company has a market capitalization of $2.14 billion, a P/E ratio of 36.16 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same quarter in the previous year, the business posted ($0.29) EPS. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. On average, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can increased its position in Supernus Pharmaceuticals by 1,508.0% during the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after buying an additional 109,088 shares in the last quarter. Marshall Wace LLP acquired a new position in Supernus Pharmaceuticals during the second quarter valued at $1,967,000. Cubist Systematic Strategies LLC boosted its holdings in Supernus Pharmaceuticals by 98.3% in the second quarter. Cubist Systematic Strategies LLC now owns 79,632 shares of the specialty pharmaceutical company’s stock valued at $2,130,000 after purchasing an additional 39,479 shares during the last quarter. Millennium Management LLC grew its position in Supernus Pharmaceuticals by 395.1% during the 2nd quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock worth $4,316,000 after purchasing an additional 128,743 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Supernus Pharmaceuticals by 7.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock valued at $710,000 after buying an additional 1,870 shares during the last quarter.

Wall Street Analyst Weigh In

SUPN has been the topic of a number of research analyst reports. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target for the company.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.